Expertise in Testing Adoptive Cell Therapies
Companies developing Adoptive Cell Therapies (ACTs), and particularly those with CAR T cell therapies, will discover in MI Bioresearch an unparalleled breadth of experience in the use of mouse tumor models to evaluate ACTs. With a broad range of disseminated and subcutaneous tumor models characterized in NSG mice, and a scientific team that knows how to apply them, we can guide selection of the right tumor model for your CAR T cell or other ACT study.
MI Bioresearch has a “sweet spot” in evaluating hematological malignancy models based on a long-standing heritage in the use of bioluminescence imaging (BLI) to track disseminated tumor burden. With over 80 unique hematological malignancy cell lines, such as the CD19+ Raji-Luc lymphoma model, the MV-411-Luc leukemia model, and the MM.1S-Luc multiple myeloma model, we lead the industry with market-relevant models for your studies. We also have an ever-expanding list of solid tumor models validated in NSG mice to support the field’s drive toward approval of an ACT in a solid tumor indication.
Explore below the range of tumor models and in vitro services that we can apply to your CAR T cell or other ACT study.
Milestones in Adoptive Cell Therapy
The technologies and services at MI Bioresearch have moved in the same direction as the ACT field putting us in a unique position to be poised for supporting CAR T cell and other ACT approaches.
Tumor Models by Histotype Being Targeted with Adoptive Cell Therapy:
BNL 1ME A.7R.1
BNL 1ME A.7R.1-Luc-mCh-Puro
|Lung [Anaplastic Carcinoma]||
Support with In Vitro Services Under the Same Roof for your ACT Studies
- Flow Cytometry
- Luminex, Cytometric Bead Array
- ELISA Assays (custom and off the shelf)
- Histology and IHC
- Proliferation assays
- High content image analysis
- Custom assay development
- Ex vivo flow cytometry
- 3D matrix assays
- Biochemical assays
MI Bioresearch is continually improving and expanding its adoptive cell therapy (ACT) capabilities. Keep checking back for updates and learn how we can help you with your next ACT study.